Catalyst Wire Dossier Catalyst Wire Dossier

REGN3051

REGN3051 · Regeneron Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for REGN3051, covering 2019-02-01 to 2019-02-01. Get the full timeline:

Most recent: Clinical Trial Update: A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051 [Phase 1]

See pricing